INCY
$INCY
Incyte Corporation
Biopharmaceutical company focused on oncology and inflammation with Jakafi as lead drug.
Healthcare$98.22
-0.77 (-0.78%)
Day Range$96.09 - $99.62
Prev Close$98.99
Analyst Rating
Buy
16 Buy / 18 Hold / 1 Sell
Subscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
INCY: Clinical Wins and Partnership, Valuation Questioned
Incyte ($INCY) posted positive Phase 3 povorcitinib data and launched an Adagene collaboration, creating clinical momentum. Valuation looks reasonable, but analyst downgrades and execution risks keep the stance neutral.
Apr 6, 2026